The Efficacy and Safety of Cobitolimod in Participants With Moderate to Severe Active Left-Sided Ulcerative Colitis

NCT04985968 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

171

Enrollment

INDUSTRY

Sponsor class

Stopped Due to futility

Conditions

Ulcerative Colitis

Interventions

DRUG: Cobitolimod 250 mg
DRUG: Cobitolimod 500 mg
DRUG: Placebo

Sponsor

InDex Pharmaceuticals